Delivery Order SPE2DB22D2206-SPE2DB24FJD15
Award Date
7/10/24
Potential Completion Date
7/11/24
Potential Value
$25K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $4,194.00, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. This is a firm fixed-price delivery order contract with a period of performance through November 15, 2024. The contract does not have a set-aside designation, indicating it was open...
This federal contract award, valued at $18,411.17, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract is a Firm Fixed Price Delivery Order with a completion date of July 17, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a larger...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,083.53 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which enables the government to...
This federal contract award, valued at $13,438.81, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication used to treat chronic dry eye. The award is a Firm Fixed Price Delivery Order contract, with a period of performance running through January 25, 2024. It is not designated as a set-aside contract....
This federal contract award, valued at $13,618.22, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order under the company's Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical...
This federal contract award is for a delivery order placed by the Defense Logistics Agency (DLA) with Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,843.23 firm fixed-price contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication used to treat dry eye disease. The contract award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with...
This federal contract award, valued at $75,226.89, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,226.27 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. The contract has a completion date of February 2, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,117.80 firm fixed-price delivery order is for the provision of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication. The contract has an ultimate completion date of March 17, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
This federal contract award, valued at $24,380.75, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication used for the treatment of dry eye disease. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical worth up...